Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy

被引：11
|
作者：
An, Xin [1 ,2 ]
Ding, Pei-Rong [1 ,3 ]
Xiang, Xiao-Juan [1 ,2 ]
Wang, Zhi-Qiang [1 ,2 ]
Wang, Feng-Hua [1 ,2 ]
Feng, Fen [1 ,2 ]
Jiang, Wen-Qi [1 ,2 ]
He, You-Jian [1 ,2 ]
Xu, Rui-Hua [1 ]
Li, Yu-Hong [1 ,2 ]
机构：
[1] State Key Lab Oncol S China, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China
来源：
BIOMARKERS | 2010年 / 15卷 / 03期
关键词：
Carcinoembryonic antigen surge; chemotherapy; irinotecan; metastatic colorectal cancer; FOLINIC ACID; COLON-CANCER; TUMOR-MARKER; CEA; EXPRESSION; 5-FLUOROURACIL; OXALIPLATIN; THERAPY; CELLS; INCREASE;
D O I：
10.3109/13547500903477377
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Methods: We retrospectively reviewed 132 patients with metastatic colorectal cancer treated with irinotecan-based chemotherapy. Incidence of a CEA surge and chemotherapy efficacy were investigated. Results: Eleven of 99 eligible patients (11.1%) had CEA surges. None of the 11 patients showed progressive disease (four had a partial response, seven had stable disease). Conclusion: A CEA surge can be induced by irinotecan-based chemotherapy. An early increase in CEA after irinotecan-based chemotherapy does not usually indicate progression of disease and failure of therapy, and should not lead to a change of chemotherapy.
引用
收藏
页码：243 / 248
页数：6
相关论文
共 50 条
  • [41] Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
    Moe, M.
    Micallef, R. A.
    Pwint, T.
    Maughan, T.
    Mort, D.
    Wagstaff, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer
    Iwanicki-Caron, Isabelle
    Di Fiore, Frederic
    Roque, Isabelle
    Astruc, Emilie
    Stetiu, Monica
    Duclos, Aude
    Tougeron, David
    Saillard, Sandrine
    Thureau, Sebastien
    Benichou, Jacques
    Paillot, Bernard
    Basuyau, Jean Pierre
    Michel, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3681 - 3686
  • [43] Does baseline level or response of carcinoembryonic antigen (CEA) predict survival in patients with metastatic colorectal cancer (CRC) treated with chemotherapy and bevacizumab?
    Stein, A.
    Cierpinski, A.
    Kutscheidt, A.
    Kindler, M.
    Kirsch, A.
    Petersen, V
    Schulze, M.
    Seraphin, J.
    Tummes, D.
    Srock, S.
    Arnold, D.
    ONKOLOGIE, 2011, 34 : 250 - 250
  • [44] Predictive value of tissue inhibitor of metalloproteinases-1 and carcinoembryonic antigen plasma levels in response to chemotherapy in patients with metastatic colorectal cancer
    Roayaei, Mahnaz
    Emami, Hamid
    Adeli, Pouria
    Rezaei, Abbas
    Akbari, Mojtaba
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2014, 19 (12): : 1129 - 1133
  • [45] Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
    Braghiroli, Maria Ignez Freitas Melro
    Filho, Daniel Santos Rocha Sobral
    Fagundes, Juliana Goes Martins
    Mendoza, Elizabeth Zambrano
    Neffa, Maria Fernanda Batistuzzo Vicentini
    Campos, Karla Souza
    da Fonseca, Leonardo Gomes
    Bonadio, Renata Colombo
    Talans, Aley
    Braghiroli, Oddone Freitas Melro
    Mathias-Machado, Maria Cecilia
    Sabbaga, Jorge
    Venchiarutti, Camila Motta
    Hoff, Paulo Marcelo Gehm
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 42
  • [46] Combination of Geriatric Nutritional Risk Index and Carcinoembryonic Antigen to Predict the Survival of Patients With Colorectal Cancer
    Xie, Hailun
    Wei, Lishuang
    Yuan, Guanghui
    Liu, Mingxiang
    Liang, Yanren
    Gao, Shunhui
    Wang, Qiwen
    Lin, Xin
    Tang, Shuangyi
    Gan, Jialiang
    FRONTIERS IN NUTRITION, 2022, 9
  • [47] Outcomes of Irinotecan-Based Chemotherapy Regimens in Elderly Medicare Patients With Metastatic Colorectal Cancer
    Obeidat, Nour A.
    Pradel, Francoise G.
    Zuckerman, Ilene H.
    DeLisle, Sylvain
    Mullins, C. Daniel
    AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2009, 7 (06): : 343 - 354
  • [48] BTH1677 in combination with cetuximab with and without irinotecan in patients with advanced metastatic colorectal cancer
    Cornelio, Gerardo H.
    Tamayo, Maria E.
    Flores, Myra L.
    Bautista, Janet B.
    Tioleco, Paulo S.
    Gargano, Michele A.
    Kurman, Michael R.
    Walsh, Richard M.
    Beliveau, Martin
    Marier, Jean-Francois
    Patchen, Myra L.
    COLORECTAL CANCER, 2016, 5 (03) : 95 - 108
  • [49] Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients
    Bajetta, E
    Beretta, E
    Di Bartolomeo, M
    Cortinovis, D
    Ferrario, E
    Dognini, G
    Toffolatti, L
    Buzzoni, R
    ONCOLOGY, 2004, 66 (02) : 132 - 137
  • [50] Irinotecan, mitomycin, and raltitrexed (CMT) combination chemotherapy in heavily pretreated colorectal cancer (CRC) patients
    Rebollo, J.
    Gonzalez, M. S.
    Calvo, E.
    Bretcha, P.
    Farre, J.
    Dussan, C.
    Duarte, M.
    Brugarolas, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345